by Reuters, Ilan Gattegno, and Israel Hayom staff
Israeli-based Nano Dimension and Accellta announce a successful "proof of concept 3-D bioprinter for stem cells" • Feasibility study could lead to the printing of "large and complex tissues and organs" and bolster various fields of medicine.
A new breakthrough in 3-D
printing could bolster regenerative medicine, says Nano Dimension
|
Photo credit: Reuters, Ilan Gattegno, and Israel Hayom staff  |
Israel has achieved another scientific
breakthrough: Israeli 3-D printer firm Nano Dimension Ltd. has
successfully lab-tested a 3-D bioprinter for stem cells, paving the way
for the potential printing of large tissues and organs, the company said
on Wednesday.
While 3-D printers are used already to create stem cells
for research, Nano Dimension said the trial, conducted with Israeli
biotech firm Accellta Ltd, showed that its adapted printer could make
large volumes of high resolution cells quickly.
Nano Dimension said the results are a "proof of concept
3-D bioprinter for stem cells." According to Nano Dimension CEO Amit
Dror, "3-D printing of living cells is a technology that is already
playing a significant role in medical research, but in order to reach
its full potential, for the field to evolve further, there is a need to
improve printing speeds, print resolution, cell control and viability as
well as cell availability and bio-ink technologies. By combining our
high-speed, high-precision inkjet capabilities with Accellta's stem cell
suspension technologies and induced differentiation capabilities led by
a world-renowned group of experienced engineers and scientists, we can
enable 3-D printing at high resolution and high volumes."
Nano Dimension, which is traded on NASDAQ and the Tel
Aviv Stock Exchange, said the technology could ultimately be used to
create cells and tissues "for drug discovery, regenerative medicine and
research."
"3-D bioprinting enabled by the two companies'
technologies means that Nano Dimension and Accellta have the potential
to accelerate high fidelity and high viability manufacturing of living
cellular products," Nano Dimension said on Wednesday. "Accellta's
unique, robust and reproducible suspension-based cell culturing systems
produce billions of high-quality stem cells per batch and represent a
transformative step in terms of stem cell production. Accellta's
technology can deliver large quantities of high quality cells which can
be an enabler for printing even large and complex tissues and organs."
Dr. Itzchak Angel, chairman and CEO of Accellta, said on
Wednesday, "We hope and believe that this will bring the mutual
capabilities and know-how of both companies to create 3-D bioprinting
solutions that combine a high-precision, high-throughput printer with
dedicated bio-ink technologies, derived from stem cells."
Reuters, Ilan Gattegno, and Israel Hayom staff
Source: http://www.israelhayom.com/site/newsletter_article.php?id=33935
Copyright - Original materials copyright (c) by the authors.
No comments:
Post a Comment